BriaCell Therapeutics (BCTX) risk factors, FY2025 10-K

BriaCell Therapeutics's FY2025 10-K, filed Oct 16, 2025, lists 27 risk factors in 6 groups. Against the prior year's 27: 3 new, 3 dropped, 8 substantially reworded.

Open BCTX in Gloom →
BriaCell Therapeutics' chart, financials and news, free in your browser.Open BCTX in Gloom →
Risk factors listed
276 groups
New this year
3vs 27 last year
Dropped
3since the prior 10-K
Substantially reworded
8of those kept
Section length
14k wordsItem 1A

What the changes say

  • BriaCell faces escalating clinical and regulatory hurdles for its cancer treatments like Bria-IMT and Bria-OTS.

What changed since the prior 10-K

New

  • NewRisks Related to Our Business

    Pre-clinical tests and Phase 1/2 clinical trials are primarily designed to test safety, to study pharmacokinetics and pharmacodynamics and to understand the side effects of product candidates at various doses and schedules

    Regulatory authorities may disagree with our clinical data or require additional studies, and early trial success may not predict later results.

  • NewRisks Related to Our Securities

    On December 18, 2024, we received a letter from the Listing Qualifications Department of Nasdaq notifying the Company that based on our shareholders’ equity, we comply with the Rules and the matter is now closed

    We recently regained compliance with Nasdaq's minimum bid price requirement after closing below $1.00 per share.

  • NewRisks Related to Our Securities

    The Company regained compliance with the Minimum Bid Price Requirement on February 12, 2025

    Under Nasdaq's Excessive Reverse Stock Split Rule, future bid price failures within one year of our August 2025 consolidation will trigger direct delisting.

Dropped

  • DroppedRisks Related to Our Business

    BriaCell in the future may acquire businesses, products or technologies that it believes complement or expand its existing business

  • DroppedRisks Related to Our Securities

    In the event that we do not regain compliance prior to the end of the compliance period, we will receive written notification that our securities are subject to delisting, at which point we may appeal the delisting determination

  • DroppedRisks Related to Our Securities

    In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been given 180 calendar days, or until February 18, 2025, to regain compliance with the Minimum Bid Price Requirement

Reworded

  • 100% rewrittenRisks Related to Our Business

    Pre-clinical studies and initial clinical trials are not necessarily predictive of future results

    The risk header was shortened and the detailed description of pre-clinical tests and Phase 1/2 trials was removed.

  • 99% rewrittenBusiness related risks

    We are a pre-revenue clinical stage company

    Replaced general discussion of profitability and commercialization risks with specific focus on operational strain and staffing growth.

  • 64% rewrittenRisks Related to Regulations

    We may not succeed in completing the development of our products, commercializing our products or generating significant revenues

  • 50% rewrittenBusiness related risks

    We are highly dependent on our key personnel

  • 45% rewrittenBusiness related risks

    A material breach in security relating to the Company’s information systems and regulation related to such breaches, cyber-attacks, or other disruptions could adversely affect the Company, expose us to liability and affect our business and reputation

  • 41% rewrittenFinancial risk

    Certain Canadian legislation contains provisions that may have the effect of delaying or preventing a change in control

  • 25% rewrittenFinancial risk

    We have a history of losses, may incur future losses and may not achieve profitability

    Updated net loss figures to $26,311,867 for fiscal 2025 compared to $4,791,466 for fiscal 2024.

  • 24% rewrittenBusiness related risks

    There is substantial doubt about our ability to continue as a going concern

    Updated net losses and accumulated deficit figures to reflect the 2025 fiscal year totals.

All 27 risk factors

Headings as the filing states them, in filing order.

Risks Related to Our Business

  1. 01Pre-clinical studies and initial clinical trials are not necessarily predictive of future results100% rewritten
  2. 02Pre-clinical tests and Phase 1/2 clinical trials are primarily designed to test safety, to study pharmacokinetics and pharmacodynamics and to understand the side effects of product candidates at various doses and schedulesNew
  3. 03We are heavily reliant on third-parties to carry out a large portion of our business

Risks Related to Our Intellectual Property

  1. 04We may not successfully develop, maintain and protect our proprietary products and technologies
  2. 05Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time

Risks Related to Regulations

  1. 06Changes in legislation and regulations may affect our revenue and profitability
  2. 07The results of our clinical trials may not support our product claims or may result in the discovery of adverse side effects
  3. 08We may not succeed in completing the development of our products, commercializing our products or generating significant revenues64% rewritten

Business related risks

  1. 09There is substantial doubt about our ability to continue as a going concern24% rewritten
  2. 10We have an unproven market for our product candidates
  3. 11We are a pre-revenue clinical stage company99% rewritten
  4. 12We may not succeed in adapting to and meeting the business needs associated with our anticipated growth
  5. 13BriaPro may not generate revenue as expected
  6. 14We are highly dependent on our key personnel50% rewritten
  7. 15A material breach in security relating to the Company’s information systems and regulation related to such breaches, cyber-attacks, or other disruptions could adversely affect the Company, expose us to liability and affect our business and reputation45% rewritten
  8. 16The Company’s international operations expose it and its representatives, agents and distributors to risks inherent to operating in foreign jurisdictions that could materially adversely affect its operations and financial position

Risks Related to Our Securities

  1. 17On December 18, 2024, we received a letter from the Listing Qualifications Department of Nasdaq notifying the Company that based on our shareholders’ equity, we comply with the Rules and the matter is now closedNew
  2. 18The Company regained compliance with the Minimum Bid Price Requirement on February 12, 2025New

Financial risk

  1. 19We have a history of losses, may incur future losses and may not achieve profitability25% rewritten
  2. 20We must obtain additional capital to continue our operations
  3. 21Future issuance of our common shares could dilute the interests of existing shareholders
  4. 22Short sellers may be manipulative and may drive down the market price of our common shares
  5. 23Sales of a substantial number of our common shares in the public market by our existing shareholders could cause our share price to fall
  6. 24We are an Emerging Growth Company, which may reduce the amount of information available to investors
  7. 25In the event a market develops for our common shares or Warrants, the market price of our common shares or Warrants may be volatile
  8. 26Certain Canadian legislation contains provisions that may have the effect of delaying or preventing a change in control41% rewritten
  9. 27We may be adversely affected by the effects of inflation

Other BriaCell Therapeutics 10-Ks

  • FY2024 10-K risk factors
    27 risks

    BriaCell faces ongoing operating losses, a going concern warning, and the need for significant additional capital to fund clinical trials.

    Filed Oct 29, 2024

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.